Theravance Biopharma, Inc. is a biopharmaceutical firm focused on discovering, developing, and bringing to market treatments for respiratory conditions across North America, Europe, and Asia. Its portfolio features YUPELRI, a daily, nebulized long-acting muscarinic antagonist (LAMA) prescribed for chronic obstructive pulmonary disease (COPD). The company also maintains a substantial pipeline of experimental medications.